Prophylactic low-dose paracetamol for ductal closure and neurodevelopmental outcome in very preterm infants.
neurodevelopmental outcome
patent ductus arteriosus
preterm infants
prophylactic paracetamol
Journal
Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
24
04
2023
received:
19
10
2022
accepted:
26
04
2023
medline:
11
7
2023
pubmed:
27
4
2023
entrez:
27
4
2023
Statut:
ppublish
Résumé
To investigate the direct effect of prophylactic low-dose paracetamol administration for ductal closure on neurodevelopmental outcome in very preterm infants who did not receive ibuprofen or surgical ligation for treatment of a patent ductus arteriosus. Infants < 32 gestational weeks born 10/2014-12/2018 received prophylactic paracetamol (paracetamol group, n = 216); infants born 02/2011-09/2014 did not receive prophylactic paracetamol (control group, n = 129). Psychomotor (PDI) and mental (MDI) outcome were assessed using Bayley Scales of Infant Development at 12 and 24 months corrected age. Our analyses showed significant differences in PDI and MDI at age 12 months (B = 7.8 (95% CI 3.90-11.63), p < 0.001 and B = 4.2 (95% CI 0.81-7.63), p = 0.016). At age 12 months, the rate of psychomotor delay was lower in the paracetamol group (OR 2.22, 95% CI 1.28-3.94, p = 0.004). There was no significant difference between the rates of mental delay at any time-point. All group differences remained significant after adjustment for potential confounders (PDI 12 months B = 7.8 (95% CI 3.77-11.34), p < 0.001, MDI 12 months B = 4.3 (95% CI 0.79-7.45), p = 0.013, PDI < 85 12 months OR 2.65 (95% CI 1.44-4.87), p = 0.002). We found no impairment of psychomotor and mental outcome at age 12 and 24 months in very preterm infants after prophylactic low-dose paracetamol administration.
Substances chimiques
Acetaminophen
362O9ITL9D
Ibuprofen
WK2XYI10QM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1706-1714Subventions
Organisme : Österreichischer Herzfonds
ID : 202001
Informations de copyright
© 2023 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica.
Références
Rozé JC, Cambonie G, Marchand-Martin L, et al. Association between early screening for patent ductus arteriosus and In-hospital mortality among extremely preterm infants. JAMA. 2015;313(24):2441-2448.
Oncel MY, Erdeve O. Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus. World J Clin Pediatr. 2016;5(1):75-81.
Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev. 2018;4:CD010061.
Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One. 2013;8(11):e77888.
Oncel MY, Yurttutan S, Erdeve O, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr. 2014;164(3):510-514. e511.
Härkin P, Härmä A, Aikio O, et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. J Pediatr. 2016;177:72-77.e72.
Hock M, Brunner B, Rier V, et al. Prophylactic low-dose paracetamol administration associated with lowered rate of patent ductus arteriosus in preterm infants - impact on outcome and pain perception. Pediatr Neonatol. 2020;61(1):84-91.
Ohlsson A, Shah PS. Paracetamol (acetaminophen) for prevention or treatment of pain in newborns. Cochrane Database Syst Rev. 2016;10:CD011219.
Marconi E, Bettiol A, Ambrosio G, et al. Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: a systematic review and network meta-analysis of clinical trials and observational studies. Pharmacol Res. 2019;148:104418.
Liew Z, Ritz B, Rebordosa C, Lee PC, Olsen J. Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatr. 2014;168(4):313-320.
Cooper M, Langley K, Thapar A. Antenatal acetaminophen use and attention-deficit/hyperactivity disorder: an interesting observed association but too early to infer causality. JAMA Pediatr. 2014;168(4):306-307.
Bornehag CG, Reichenberg A, Hallerback MU, et al. Prenatal exposure to acetaminophen and children's language development at 30 months. Eur Psychiatry. 2018;51:98-103.
Baker BH, Lugo-Candelas C, Wu HT, et al. Association of Prenatal Acetaminophen Exposure Measured in meconium with risk of attention-deficit/hyperactivity disorder mediated by frontoparietal network brain connectivity. JAMA Pediatr. 2020;174(11):1073-1081.
Avella-Garcia CB, Julvez J, Fortuny J, et al. Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms. Int J Epidemiol. 2016;45(6):1987-1996.
Ystrom E, Gustavson K, Brandlistuen RE, et al. Prenatal exposure to acetaminophen and risk of ADHD. Pediatrics. 2017;140(5), e20163840.
Bittker SS, Bell KR. Postnatal acetaminophen and potential risk of autism Spectrum disorder among males. Behav Sci (Basel). 2020;10(1), 26.
Liew Z, Ritz B, Virk J, Arah OA, Olsen J. Prenatal use of acetaminophen and child IQ: a Danish cohort study. Epidemiology. 2016;27(6):912-918.
Alemany S, Avella-Garcia C, Liew Z, et al. Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: meta-analysis in six European population-based cohorts. Eur J Epidemiol. 2021;36(10):993-1004.
Viberg H, Eriksson P, Gordh T, Fredriksson A. Paracetamol (acetaminophen) administration during neonatal brain development affects cognitive function and alters its analgesic and anxiolytic response in adult male mice. Toxicol Sci. 2014;138(1):139-147.
Bauer AZ, Kriebel D. Prenatal and perinatal analgesic exposure and autism: an ecological link. Environ Health. 2013;12(1):1-13.
Schreiner C, Sappler M, Hock M, et al. Prophylactic low-dose paracetamol Administration for Ductal Closure and Amplitude-Integrated Electroencephalography in preterm infants. Front Pediatr. 2022;10:887614.
Sappler M, Hammerl M, Pellkofer Y, et al. Prophylactic low-dose paracetamol Administration for Ductal Closure and Microstructural Brain Development in preterm infants. Neonatology. 2022;1-9:361-369.
Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013;13:13.
Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187(1):1-7.
Kidokoro H, Anderson PJ, Doyle LW, Woodward LJ, Neil JJ, Inder TE. Brain injury and altered brain growth in preterm infants: predictors and prognosis. Pediatrics. 2014;134(2):E444-E453.
Aikio O, Härkin P, Saarela T, Hallman M. Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants. J Matern Fetal Neonatal Med. 2014;27(12):1252-1256.
Bayley N. Bayley Scales of Infant and Toddler Development® 3rd Edition (Bayley-III®). The Psychological Corporation; 2006.
Reuner GRJ. Bayley Scales of Infant and Toddler Development, Bayley-Iii, Third Edition, German Version. Frankfurt; 2014.
Kiechl-Kohlendorfer U, Biermayr M, Pupp Peglow U, Griesmaier E. Outcome of infants born at < 32 weeks' gestation in a single-Centre level III neonatology unit - relation to feeding strategy. J Int Med Res. 2018;46(12):5107-5116.
Juujärvi S, Kallankari H, Pätsi P, et al. Follow-up study of the early, randomised paracetamol trial to preterm infants, found no adverse reactions at the two-years corrected age. Acta Paediatr. 2019;108(3):452-458.
Juujärvi S, Saarela T, Hallman M, Aikio O. Trial of paracetamol for premature newborns: five-year follow-up. J Matern Fetal Neonatal Med. 2021;35:1-3.
Valeri BO, Holsti L, Linhares MB. Neonatal pain and developmental outcomes in children born preterm: a systematic review. Clin J Pain. 2015;31(4):355-362.
Johnson S, Moore T, Marlow N. Using the Bayley-III to assess neurodevelopmental delay: which cut-off should be used? Pediatr Res. 2014;75(5):670-674.
Fuiko R, Oberleitner-Leeb C, Klebermass-Schrehof K, Berger A, Brandstetter S, Giordano V. The impact of norms on the outcome of children born very-preterm when using the Bayley-III: differences between US and German norms. Neonatology. 2019;116(1):29-36.